Innovative Medicine — Total Assets
Business Segments · Total AssetsJohnson & Johnson Innovative Medicine — Total Assets decreased by 1.4% to $74.42B in Q3 2025 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2022
Last reportedQ3 2025
Rolls up toTotal Assets
How to read this metric
An increase indicates capital expansion or investment in the segment, while a decrease may suggest divestitures or asset depreciation.
Detailed definition
This represents the total book value of assets specifically allocated to or utilized by the Innovative Medicine segment....
Peer comparison
Standard segment asset reporting required for segment-level financial analysis in large diversified firms.
Metric ID:
jnj_segment_innovative_medicine_assetsHistorical Data
6 periods
| Q4 '22 | Q4 '23 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|
| Value | $58.44B | $58.32B | $57.07B | $58.73B | $75.49B | $74.42B |
| QoQ Change | — | -0.2% | -2.2% | +2.9% | +28.5% | -1.4% |
| YoY Change | — | -0.2% | -2.2% | — | — | — |
Range$57.07B – $75.49B
CAGR+21.3%
Avg YoY Growth-1.2%
Median YoY Growth-1.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — total assets?
- Johnson & Johnson (JNJ) reported innovative medicine — total assets of $74.42B in Q3 2025.
- What does innovative medicine — total assets mean?
- The total value of all assets, such as equipment and intellectual property, held by the pharmaceutical segment.